Race against time: faster clotting drug tested in transplant patients

NCT ID NCT07265843

Summary

This study aims to see if using a room-temperature blood-clotting product (IFC) leads to better outcomes than a frozen product (cryoprecipitate) for liver transplant patients who are bleeding and have low clotting factors. Researchers will compare how much blood patients need and other measures over 24 hours. The goal is to control bleeding more effectively during this critical surgery.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANT SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Cincinnati

    Cincinnati, Ohio, 45221, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.